Aprepitant to Improve Same Day Discharge for TKA

Part of paid clinical trials in Skokie, Illinois.

Sponsor
Endeavor Health
Study ID
NCT07639723
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • PONV

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Aprepitant Injection — DRUG
    32mg aprepitant will be administered intravenously preoperatively during single sided total knee arthroscopy
  • Ondansetron (Zofran) — DRUG
    4 mg IV ondansetron will be given at surgical closure during total knee arthroscopy
  • Dexamethasone — DRUG
    4 mg IV dexamethasone will be given after induction of MAC sedation anesthesia during total knee arthroscopy
  • Placebo — OTHER
    Patients will receive 32 mg of intravenous (IV) placebo preoperatively for a total knee arthroscopy

Study Details

The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.

Key Dates

Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
Jul 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
350 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: aprepitant
    Single intravenous (IV) bolus of 32mg aprepitant preoperatively , in addition to the standard antiemetic protocol (4 mg IV dexamethasone after induction of MAC sedation anesthesia and 4 mg IV ondansetron at surgical closure)
  • Placebo Comparator: Placebo
    Single intravenous (IV) bolus of 32mg of placebo preoperatively, in addition to the standard antiemetic protocol (4 mg IV dexamethasone after induction of MAC sedation anesthesia and 4 mg IV ondansetron at surgical closure)

Primary Outcome Measure

difference in the incidence of same-day discharges between two randomized groups of anti-emetic regimens for anesthesia care [ Time Frame: patients will be followed from arrival for surgery to 7 days post operatively ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Endeavor Health Skokie HospitalSkokieIllinois60076
Jessica Brickner
[email protected]
847-570-1197
Nia Moragne
[email protected]
847-570-1197
Steven Greenberg, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Skokie, IL

By research site
Endeavor Health Skokie Hospital· Skokie, IL

Related Studies